Oral anticoagulants for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

Direct oral anticoagulants (DOACs) and vitamin K antagonists (VKA) are currently prescribed in Switzerland for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). Based on evidence from an observational study, an external applicant requested the FOPH to re-evaluate the use of DOACs for NVAF in Switzerland. The aim of this HTA is to evaluate the efficacy, effectiveness, safety, cost-effectiveness and budgetary impact of DOACs compared to VKAs for the prevention of stroke and other thromboembolic events in patients diagnosed with NVAF.

Dokumente

HTA protocol (PDF, 353 kB, 29.04.2022)

Stakeholder feedback on the scoping report (PDF, 983 kB, 29.04.2022)

Last modification 29.04.2022

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

Main Navigation

FOPH

Search

Breadcrumb

Oral anticoagulants for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

Dokumente

Contact